How is sapropterin involved in creating functional enzymes?

How does sapropterin help restore enzyme function in PKU?

Sapropterin supplies the tetrahydrobiopterin (BH4) cofactor that phenylalanine hydroxylase needs to convert phenylalanine into tyrosine. In responsive patients the drug stabilizes the mutant enzyme and increases its residual activity, lowering blood phenylalanine without dietary restriction alone.

What determines whether a patient responds to sapropterin?

Response depends on the specific PAH gene variant; some mutations still allow partial folding or cofactor binding, while others destroy catalytic activity completely. A four-week trial measuring phenylalanine reduction identifies responders, who typically show at least a 20–30 percent drop.

Why do some mutations respond while others do not?

Missense variants that preserve the active site but impair BH4 binding or protein stability can be rescued by extra cofactor. Nonsense, frameshift, or severe splicing mutations eliminate functional protein and show no benefit from sapropterin.

When does patent protection for sapropterin end?

The primary U.S. composition-of-matter patent for Kuvan expired in 2020; generic versions are now marketed, and several abbreviated new drug applications have been approved [1].

Who makes generic sapropterin?

Manufacturers include Dr. Reddy’s, Sun Pharma, and Teva; each product must demonstrate bioequivalence to the reference listed drug under current FDA guidance.

What monitoring do patients need after starting sapropterin?

Clinicians track weekly blood phenylalanine for the first month, then monthly, adjusting dose (5–20 mg/kg/day) and diet to keep levels in the target range of 120–360 µmol/L.

How does sapropterin compare with pegvaliase?

Pegvaliase is an injectable enzyme substitution that directly degrades phenylalanine and works regardless of PAH genotype, whereas sapropterin only augments existing enzyme activity and benefits roughly 20–30 percent of patients.

Can sapropterin be used in pregnancy?

Current guidelines allow continuation in responsive women when dietary control alone is insufficient, with close metabolic monitoring to avoid both elevated maternal phenylalanine and potential fetal BH4-related effects.

[1] DrugPatentWatch.com